SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE, Inc. director Jeffrey W. Dunn reported a series of transactions in the company’s common stock. On December 8, 2025, he exercised a stock option for 1,241 shares at an exercise price of $4.32 per share and acquired those shares.
That same day, he sold 1,241 shares of common stock and separately sold another 18,759 shares, both reported with a weighted-average sale price of $19.3297 per share, with individual sale prices ranging from $19.13 to $19.85. The sales were made under a Rule 10b5-1 trading plan dated May 7, 2025. After these transactions, he beneficially owned 10,307 shares directly, including shares issuable on settlement of restricted stock units, and 110,115 shares indirectly through The Jeffrey W. Dunn Living Trust dated May 17, 2012.
SI-BONE, Inc. (SIBN) reported an insider transaction by its SVP, Ops & Adm/Chief Legal Officer. On 11/24/2025, the officer sold 400 shares of common stock at $20 per share, reported with transaction code "S" for a sale. The filing notes that this trade was made under a Rule 10b5-1 trading plan dated June 13, 2025, which is a pre-arranged plan for selling shares.
After this transaction, the reporting person beneficially owned 251,496 shares of SI-BONE common stock. This total includes 125,823 shares issuable upon settlement of restricted stock units, where each unit represents the right to receive one share of common stock.
SI-BONE, Inc. (SIBN) filed a Form 4 reporting stock sales by its Chief Financial Officer, Anshul Maheshwari. The CFO sold 1,200 shares of common stock on 11/21/2025 at a weighted-average price of about $20.0133 per share and an additional 100 shares on 11/25/2025 at $20.00 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 13, 2024, which is designed to allow insiders to sell stock according to a set schedule.
Following these transactions, Maheshwari beneficially owns 203,773 shares of SI-BONE common stock. This total includes 143,116 shares issuable upon settlement of restricted stock units, each representing a right to receive one share of common stock.
SI-BONE, Inc. (SIBN) reported an insider transaction by its President, Commercial Ops, Anthony J. Recupero. On 11/17/2025, he sold 1,707 and 2,126 shares of common stock in two transactions at weighted average prices of $17.4232 and $17.4462, respectively. These sales were made to cover tax withholding obligations arising from the vesting of restricted stock units and are described as non-discretionary “sell to cover” trades.
Following these transactions, the reporting person beneficially owned 268,144 shares of SI-BONE common stock, including 133,316 shares issuable upon settlement of restricted stock units, with each unit representing a contingent right to receive one share.
SI-BONE, Inc. (SIBN) reported an insider transaction by its Senior Vice President, Operations & Administration and Chief Legal Officer on 11/17/2025. The executive sold 1,478 and 1,850 shares of common stock in two separate trades, coded as sales.
According to the disclosure, these sales were made solely to cover tax withholding obligations arising from the vesting of restricted stock units under a "sell to cover" arrangement and are described as non-discretionary trades. After the transactions, the reporting person beneficially owned 251,896 shares of common stock, including 125,823 shares issuable upon settlement of restricted stock units, each unit representing a right to receive one share.
SI-BONE, Inc. insider trading report: The Chief Financial Officer of SI-BONE, Inc. (SIBN) reported two sales of common stock on 11/17/2025 totaling 3,460 shares. One sale covered 1,275 shares at a weighted average price of $17.4098, and another covered 2,185 shares at a weighted average price of $17.4369. According to the disclosure, these transactions were "sell to cover" sales required to satisfy tax withholding obligations related to vesting restricted stock units and were not discretionary trades. After these transactions, the reporting person beneficially owned 205,073 shares of common stock, including 143,116 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) reported insider transactions by Chief Executive Officer and Director Laura A. Francis. On 11/17/2025, she sold several small blocks of common stock, including 2,028 shares at a weighted average price of $17.4401, 2,231 shares at $17.4449, 3,197 shares at $17.4341, and 3,885 shares at $17.3996.
The filing explains that these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units and were executed as "sell to cover" transactions rather than discretionary trades. On 11/18/2025, 5,411 additional shares were sold at a weighted average price of $17.6978 under a Rule 10b5-1 trading plan dated December 13, 2024.
After these transactions, Francis beneficially owned 408,363 shares directly, including 373,980 shares issuable upon settlement of restricted stock units, and 351,319 shares indirectly through a trust.
SI-BONE (SIBN) reported an insider transaction by CEO and Director Laura A. Francis. She sold 5,411 shares of common stock on 11/11/2025 at a weighted‑average price of $17.0591, effected under a Rule 10b5-1 trading plan dated December 13, 2024.
After the sale, 356,730 shares were held indirectly by a trust, and 419,704 shares were held directly. The direct figure includes 396,297 shares issuable upon settlement of restricted stock units.
SI-BONE (SIBN) director Jeffrey W. Dunn reported option exercises and related sales on 11/11/2025. He exercised stock options at $4.32 for 23,148 shares and 56,852 shares, then sold the same amounts at $18.95 per share pursuant to a Rule 10b5-1 trading plan dated May 7, 2025.
Following these transactions, he directly held 10,307 shares. He also had indirect ownership of 118,874 shares held by The Jeffrey W. Dunn Living Trust. The direct total includes 10,307 shares issuable upon settlement of restricted stock units, each representing one share of common stock. The option awards referenced vest in equal monthly installments over four years, subject to continued service.
SI-BONE (SIBN) reported a Form 4 for CFO Anshul Maheshwari. On 11/11/2025, he sold 2,601 shares of common stock at a weighted-average price of $18.3333, executed under a Rule 10b5-1 trading plan dated December 13, 2024. Following the sale, he beneficially owns 208,533 shares, which include 150,203 shares issuable upon settlement of restricted stock units. Ownership is listed as direct.